About Gene Solutions
Gene Solutions is an international biotechnology company based in Singapore, driving advancements in genetic testing and research innovation. By integrating Next-Generation Sequencing (NGS) and Artificial Intelligence, the company offers a comprehensive portfolio of advanced solutions, including:
- Reproductive Health: Next-generation Non-invasive Prenatal Testing (NIPT), which covers both fetal abnormalities and maternal health indicators.
- Clinical Oncology:
- Multi-cancer Screening using multi-omics circulating tumor DNA (ctDNA) technology for early detection and tumor-of-origin localization.
- Comprehensive Genomic and Transcriptomic Profiling (CGTP) combined with clinically validated ctDNA-based molecular residual disease (MRD) monitoring to guide precision treatment and track disease progression.
- Multi-cancer Screening using multi-omics circulating tumor DNA (ctDNA) technology for early detection and tumor-of-origin localization.
- Comprehensive Genomic and Transcriptomic Profiling (CGTP) combined with clinically validated ctDNA-based molecular residual disease (MRD) monitoring to guide precision treatment and track disease progression.
With over three million genetic tests delivered worldwide since 2017, Gene Solutions is recognized for its proprietary research, CAP-accredited laboratories, and contributions to advancing precision medicine through clinical studies, technology development, and regional collaborations.
Eight Years of Research and Clinical Trials conducted By Dedicated Molecular Biologists, Bioinformaticians and Medical Oncologists
Publications
Over 50+ peer-reviewed publications, with more than 20 focused on oncology in top journals like Nature Scientific Reports, eLife Sciences, BioMed Central, Frontiers in Oncology, and ESMO publications.
Awards & Presentations
18 award-winning abstracts and oral presentations at prestigious international oncology conferences, including the ASCO Annual Meeting, ASCO Breakthrough, and ESMO Asia.
Pioneering applications of ctDNA transforming personalized cancer care
High-sensitivity assays interpreted with AI-powered analytics to identify circulating tumor DNA (ctDNA) in the bloodstream.
Early cancer
detection by ctDNA
The SPOT-MAS test utilizes next-generation sequencing (NGS) and artificial intelligence (AI) to analyze multiple characteristics of circulating tumor DNA (ctDNA) from blood. This advanced approach enables the early detection of the most common and aggressive cancers.
- 99.8% Specificity *
- 99.9% Negative Predictive Value (NPV)
- 78.1% Sensitivity
- 84% Tumor location prediction (TOO) accuracy
* The performance of SPOT-MAS has been proven in multiple studies and a clinical validation involving 9,024 participants: Le Son Tran et al. Analytical and clinical validation of a circulating tumor DNA-based assay for multicancer early detection.. JCO 42, 10548-10548(2024).DOI:10.1200/JCO.2024.42.16_suppl.10548
Visit product website at: www.spotmas.comGenomic Profiling and Personalized Cancer Monitoring
- Comprehensive Genomic Profiling (155-504 gene-panels): Actionable/resistant mutations, Germline mutations, Microsatellite Instability (MSI), with option for PD-L1 & Tumor Mutational Burden (TMB).
- Personalized ctDNA profiling for Minimal Residual Disease (MRD) detection, recurrence prognosis, relapse tracking and treatment response monitoring.
- Pan-cancer analysis in both early or metastatic stages.
